ZURICH--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim. This milestone marks continued progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases. The candidate is a trispecific M-gager®, an antibody-based T
CDR-Life Announces First Milestone Achievement in Boehringer Ingelheim Autoimmune Partnership
